Dr Heng Mei speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about improving the safety of CAR T-cell therapy by controlling CRS-related coagulopathy.
He reports that the phase I study found that early and proper interventions targeted at CRS-related coagulopathy are important in controlling side effects with the therapy.
Dr Mei says that the next steps for the study are to include more patients and to do multiple-centre research, potentially with collaborators from Europe.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.